Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat with Gem/Bu/Mel Conditioning for Lymphoma ASCT
NCT02961816Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of panobinostat in diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), T-cell lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Planned start Jun 2017; status: withdrawn.
02
Drugs
panobinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)Hodgkin lymphoma (HL)T-cell lymphoma
Beyond the preview
Go deeper on NCT02961816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961816.